Wednesday, April 21, 2021
ENGELWOOD — Zynex, Inc. (Nasdaq: ZYXI) introduced that it has been adopted Donald Gregg as VP gross sales and operations of the monitoring options division.
Gregg will lead the division’s operations, gross sales, advertising and product improvement, together with the manufacturing and launch of the CM-1500 Blood Volume Monitor, which obtained 510(ok) approval from the U.S. Food and Drug Administration in 2020.
“I am excited to bring on Donald to lead our monitoring solutions division. We will continue to grow this division by adding staff across clinical research and sales and marketing,” stated Thomas Zandgaard, Zynex Founder and CEO.
“With Donald’s background, I am confident that our technology will soon become the standard of care for the early detection of internal bleeding in surgical and postoperative recovery. While the CM-1500 is already in full production, the next generation (CM-1600) is well underway and we hope to file for FDA approval for that model soon.”
Zynex stated Gregg brings a wealth of expertise to the corporate. He beforehand held management roles as VP and GM of infusion programs at Smith Medical and senior director of product, advertising and enterprise improvement of well being informatics and monitoring at Medtronic.
Gregg efficiently constructed a direct gross sales pressure, launched and commercialized infusion merchandise, distant affected person monitoring and scientific choice making software program purposes. As a results of innovating new merchandise, executing gross sales plans and creating strategic distribution and collaboration agreements, every of those firms grew by double digits.
Gregg holds a Bachelor of Science in Marketing from Metropolitan State University, a Master of Business Administration from the University of Phoenix, govt schooling in Healthcare and Medical Technology Management from the University of St. Thomas, and has served as a board advisor to med-tech startups.
.
Source: www.innovationews.com